Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant (JNJ-42847922) on Sleep in MDD with Insomnia
NCT02067299Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of seltorexant in Insomnia and major depressive disorder (MDD) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Latency to Persistent Sleep at Day 1. Started Feb 2014; status: completed.
02
Drugs
seltorexant
03
Conditions
Insomniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02067299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02067299.